PepGen Inc.

PepGen Inc.

PEPG·NASDAQ

$1.46

+3.0%
HealthcareBiotechnology

PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.

At a Glance

Live Snapshot
Market Cap$101.28M
EPS-2.1200
P/E Ratio-0.69
Earnings Date08/06/2026

pepg

Stock Based Compensation

Last Annual Value

10.61M

3-Year CAGR

31%

5-Year CAGR

145%

10-Year CAGR

%

PepGen Inc.

PepGen Inc. Competitors Analysis of Stock Based Compensation

PEPG · NASDAQ
CompanyStock Based Compensation
CAGR 3Y
CAGR 5Y
CAGR 10Y
PEPG logo
PepGen Inc.
NASDAQ:PEPG
10.61M
14.6%47.2%N/A 
ALEC logo
Alector, Inc.
NASDAQ:ALEC
26.66M
-14.6%-8.2%29.8%
NKTX logo
Nkarta, Inc.
NASDAQ:NKTX
8.56M
-20.8%-10.0%N/A
13.47M
22.3%3.8%N/A
6.05M
142.6%N/AN/A
8.11M
41.0%104.4%N/A
19.10M
-11.2%-2.4%N/A
1.35M
-34.0%-6.5%N/A
8.69M
-21.8%-19.8%N/A
19.58M
62.2%61.9%16.3%
6.29M
N/A-7.9%7.1%
PepGen Inc.

PepGen Inc. Fair Value Envelope

PEPG · NASDAQ

Our analysis suggests that PEPG has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $1.4642, this represents a potential HIDDEN relative to our calculated worth for PepGen Inc..

Intrinsic Value
Current Price: $1.4642